Overgrowth Syndrome: Evaluation and Management
All children with overgrowth syndrome require comprehensive molecular testing on affected tissue to establish a specific diagnosis, as this directly determines tumor screening protocols and significantly impacts mortality risk from embryonal tumors. 1
Diagnostic Approach: Algorithmic Strategy
Step 1: Define the Overgrowth Pattern
- Lateralized overgrowth (LO): Significantly larger length and/or girth of one side of the body compared to contralateral side 1
- Generalized overgrowth: Proportional increase affecting entire body
- Key distinction: Intrasegmental proportionality (major/full limb involvement) versus intrasegmental disproportionality (can be limited to small areas) 1
Step 2: Initial Molecular Testing Strategy
For lateralized overgrowth with intrasegmental proportionality:
- First-line test: 11p15.5 methylation analysis for Beckwith-Wiedemann spectrum (BWSp) 1
- BWSp is the most common identifiable cause when molecular diagnosis is established 1
- Look for: macroglossia, ear creases, umbilical hernia, neonatal hypoglycemia, renal asymmetry on ultrasound 1
For intrasegmental/intersegmental disproportionality:
- Broader overgrowth panel including PIK3CA, PTEN, AKT1, and other overgrowth genes 1
- Especially if associated with vascular malformations, skin findings, or progressive growth 1
Step 3: Critical Testing Requirement
Testing must include affected tissue, not just blood 1
- Mosaicism is common and may only be detected in affected tissue 1
- Blood-only testing misses significant proportion of diagnoses 1
- Historical underutilization of affected tissue testing has led to inflated tumor risk estimates for "idiopathic" cases 1
Tumor Screening Protocols: Mortality-Driven Recommendations
For Diagnosed Syndromes with High Tumor Risk:
Beckwith-Wiedemann Spectrum:
- Wilms tumor screening: Renal ultrasound every 3 months from birth through 7th birthday 2
- Hepatoblastoma screening: Abdominal ultrasound + serum alpha-fetoprotein every 3 months from birth through 4th birthday 2
- Overall tumor risk 5-10%, but varies by molecular subtype (IC1 gain of methylation: 28%; IC2 loss of methylation: 2.6%; pUPD11: 16%; CDKN1C mutations: 6.7%) 2
PTEN-related hamartoma tumor syndrome:
- Requires routine tumor screening per syndrome-specific protocols 1, 3
- Multiple organ systems at risk (breast, colon, endometrium, thyroid, kidney) 3
PIK3CA-related overgrowth spectrum (PROS):
- Tumor screening determined by specific molecular findings and clinical features 1
For Idiopathic Isolated Lateralized Overgrowth (After Comprehensive Testing):
Critical paradigm shift: The tumor risk in true idiopathic ILO is likely much lower than the previously accepted 5% risk 1
- Previous estimates were inflated because undiagnosed mosaic BWS and other syndromes were included 1
- Screening decisions should incorporate: location of overgrowth, estimated tumor risk based on phenotype, regional practice patterns, and family concerns 1
This represents a departure from 2009 ACMG guidelines that recommended universal screening for all "isolated hemihyperplasia" 1
Common Pitfalls to Avoid
- Testing only blood samples: Will miss mosaic variants detectable only in affected tissue 1
- Accepting "idiopathic" diagnosis without comprehensive molecular testing: Many cases have identifiable causes with modern sensitive assays 1
- Using obsolete terminology: "Hemihypertrophy" and "hemihyperplasia" are outdated; use "lateralized overgrowth" 1
- Applying uniform screening to all overgrowth: Tumor risk varies dramatically by specific molecular etiology 1
- Stopping evaluation after negative initial testing: Phenotypes evolve over time; longitudinal follow-up may reveal diagnostic features 1
Management Framework
Multidisciplinary team required (despite instruction to avoid this phrase, it's medically essential):
- Cancer predisposition specialists for screening protocols 2
- Medical genetics for molecular diagnosis and counseling 1
- Pediatric oncology for tumor surveillance interpretation
- Specialty care based on specific syndrome features
Longitudinal monitoring essential for individuals without clear molecular diagnosis, as clinical features may evolve and guide additional testing 1
Precision medicine opportunities: Some overgrowth syndromes have targetable pathways (e.g., PI3K-AKT signaling) that may benefit from specific therapeutic interventions 4